Hormone Replacement Therapy

Lifestyle changes and non-hormonal medications are recommended to maintain bone strength if necessary. For some women, hormone therapy can increase their chances of blood clots, heart attacks, strokes, breast cancer, and gallbladder disease. Certain types of HRT are at increased risk, and each woman’s own risks can vary depending on her medical history and lifestyle. If you decide to take HRT, it should be the lowest dose that helps and for the shortest time needed. The word “bioidentical” is sometimes used by marketers to describe hormonal supplements that contain estrogen and progesterone with the same chemical structure as occurs naturally in humans.

The risk was higher for women who were currently taking estrogen and decreased over time after estrogen stopped. For decades, women have used hormone therapy to Hormone Replacement Therapy Madison relieve menopausal symptoms such as hot flashes and sweating. This is called hormone therapy during menopause, and you may see it abbreviated as HT or MHT.

Breast cancer in these women was larger and had been more likely to spread to the lymph nodes at the time of diagnosis. The risk of breast cancer was higher the longer the women took the combined hormone therapy, but decreased significantly when the use of hormones was discontinued. HERS researchers tested in a secondary prevention study whether estrogen plus progestin would prevent a second heart attack or another coronary event.

The researchers found that adding progestin to estrogen provided protection against uterine cancer. As a result, progestin was added to the HT regimens prescribed for women with an intact uterus. Estrogen therapy, estrogen/progestin therapy, and hormone therapy are terms that refer to the administration of estrogen or estrogen/progestin for the purpose of suppressing hot flashes. Side effects of hormone therapy include headache, nausea, chest pain, blood clots, breast cancer, heart disease, abnormal vaginal bleeding, stroke, and uterine cancer. In the NCI study of hormone therapy and ovarian cancer, researchers looked at data from a large study that included 23,722 women with hysterectomies and 73,483 women with the uterus intact. Their goal was to find out if the use of hormones during menopause affects the risk of ovarian cancer.

You may also hear it described as hormone replacement therapy, postmenopausal hormone therapy, or postmenopausal hormones. Menopause is the phase of a woman’s life when estrogen and progesterone levels decrease. In some women, this decreased production of female hormones causes symptoms such as hot flashes and vaginal dryness, as well as physical changes such as bone weakening.

Scientists continue to learn about the effects of HTN on the heart and blood vessels. Many large clinical trials have tried to answer questions about high blood pressure and heart disease. Some have shown positive effects in women who started high blood pressure within 10 years of menopause; Some have shown negative effects when they start menopause over 10 years. Some studies have raised more questions about the potential benefits of HTN.

HT is often prescribed to prevent this condition, and HTN appears to be especially effective when started in the first 5 years after the onset of menopause. Women who have decreased bone mineral density and those with a known history of osteoporotic fractures benefit from HTN. Women with premature menopause also benefit from the bone-protecting effects of HTN.

This was a multi-faceted study that included two randomized, double-blind, placebo-controlled studies of postmenopausal hormone therapy. The use of pure estrogen HRT increases the risk of endometrial cancer, but this risk is not seen with continued treatment in combination with estrogen and progestin. One study looked at estrogen therapy in postmenopausal women who did not have a uterus.

Bioidentical hormones, which are prescribed and put together to measure, are an alternative to standard HRT drugs. Although they have been in use for many years, there is some controversy about their safety. Chemically, bioidentically, and standard HRT drugs are the same as those produced in the body.

The risk of ovarian cancer was higher in women who received hormone therapy during menopause than in women who had never used such therapy. However, the increased risks differed in the formulation and regimen of hormone therapy and varied depending on the women’s hysterectomy status. The special combination of hormone therapy that we use is also very patient-dependent. Estrogen alone cannot be administered because it can promote overgrowth of the lining of the uterus and potentially increase the risk of endometrial cancer.